MetaVia Price to Free Cash Flow Ratio 2015-2024 | MTVA

MetaVia price to free cash flow ratio from 2015 to 2024. Price to free cash flow ratio can be defined as

MetaVia Price to Free Cash Flow Ratio 2015-2024 | MTVA

MetaVia price to free cash flow ratio from 2015 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$147B
Vertex Pharmaceuticals (VRTX)$120.6B
Gilead Sciences (GILD)$115.1B
Bristol Myers Squibb (BMY)$114.9B
CSL (CSLLY)$86.6B
Regeneron Pharmaceuticals (REGN)$84.9B
GSK (GSK)$71.4B
Argenex SE (ARGX)$36.6B
Alnylam Pharmaceuticals (ALNY)$32.8B
BioNTech SE (BNTX)$28.4B
Illumina (ILMN)$23.4B
Biogen (BIIB)$22.9B
BeiGene (BGNE)$18B
Moderna (MRNA)$16.5B
Genmab (GMAB)$14.3B
Incyte (INCY)$14B
Insmed (INSM)$13.3B
BioMarin Pharmaceutical (BMRN)$12.6B
Bio-Techne Corp (TECH)$12.2B
Sarepta Therapeutics (SRPT)$12B
Exact Sciences (EXAS)$11.7B
Vaxcyte (PCVX)$11.3B
QIAGEN (QGEN)$10.5B
Exelixis (EXEL)$10.1B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$8.9B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$8.7B
Ascendis Pharma (ASND)$8.1B
Revolution Medicines (RVMD)$7.8B